A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components

Pharmaceutical Statistics

Volumn 15, Issue 5, 2016, Pages 430-437

  Dong, Gaohong ^a   Li, Di ^b   Ballerstedt, Steffen ^c   Vandemeulebroecke, Marc ^c  

^a iStats Inc   (United States)

^b EISAI INC   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

composite endpoint; odds ratio; U statistic; unmatched pair approach; Win ratio

Indexed keywords

ANALYTIC METHOD; BOOTSTRAPPING; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LIVER GRAFT; ODDS RATIO; PHASE 3 CLINICAL TRIAL; SAMPLE SIZE; STATISTICAL MODEL; STATISTICS; THEORETICAL MODEL;

EID: 84987784950     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.1763     Document Type: Article

References (26)

1. EUnetHTA (European network for Health Technology Assessment). Endpoints used for relative effectiveness assessment of pharmaceuticals - Composite endpoints, 2013. Available at: http://www.eunethta.eu/sites/5026.fedimbo.belgium.be/files/Composite\%20endpoints.pdf (accessed 30.04.2016).
2. Alosh M, Bretz F, Huque M. Advanced multiplicity adjustment methods in clinical trials. Statistics in Medicine 2014;33(4): 693–713.
3. Sankoh AJ, Li H, D'Agostino Sr RB. Use of composite endpoints in clinical trials. Statistics in Medicine 2014;33(27): 4709–4714.
4. European Medicines Agency (EMA). Guideline on the evaluation of medicinal products for cardiovascular disease prevention, 2008. Available at: http://www.ema.europa.eu/docs/en\_GB/document\_library/Scientific\_guideline/2009/09/WC500003290.pdf (accessed 30.04.2016).
5. European Medicines Agency (EMA). Points to consider on multiplicity issues in clinical trials, 2002. Available at: http://www.ema.europa.eu/docs/en\_GB/document\_library/Scientific\_guideline/2009/09/WC500003640.pdf (accessed 30.04.2016).
6. Food and Drug Administration. Guidance for Industry: Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products — Content and Format, 2006. Available at: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127534.pdf (accessed 30.04.2016).
7. Claggett B, Wei LJ, Pfeffer MA. Moving beyond our comfort zone. European Heart Journal 2013;34(12): 869–871.
8. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. Journal of the American Statistical Association 1989;84: 1064–1072.
9. Wei LJ, Glidden DV. An overview of statistical methods for multiple failure time data in clinical trials. Statistics in Medicine 1997;16(8): 833–839.
10. Sampson UK, Metcalfe C, Pfeffer MA, Solomon SD, Zou KH. Composite outcomes: weighting component events according to severity assisted interpretation but reduced statistical power. Journal of Clinical Epidemiology 2010;63: 1156–1158.
11. Ariti CA, Cleland JG, Pocock SJ, Pfeffer MA, Swedberg K, Granger CB, McMurray JJ, Michelson EL, Ostergren J, Yusuf S. Days alive and out of hospital and the patient journey in patients with heart failure: insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. American Heart Journal 2011;162(5): 900–906.
12. Bakal JA, Westerhout CM, Armstrong PW. Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials. Statistical Methods in Medical Research 2015;24(6): 980–988.
13. Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. European Heart Journal 2012;33(2): 176–82.
14. Tong BC, Huber JC, Ascheim DD, Puskas JD, Ferguson Jr TB, Blackstone EH, Smith PK. Weighting composite endpoints in clinical trials: essential evidence for the heart team. Annals of Thoracic Surgery 2012;94(6): 1908–1913.
15. Wang D, Pocock SJ. A win ratio approach to comparing ordinal or non-normal outcomes in clinical trials (presentation). In 2nd Clinical Trials Methodology Conference: Methodology Matters: Edinburgh, UK, November 18-19, 2013.
16. Rogers JK, Pocock SJ, McMurray JJ, Granger CB, Michelson EL, Östergren J, Pfeffer MA, Solomon SD, Swedberg K, Yusuf S. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. European Journal of Heart Failure 2014;16(1): 33–40.
17. Prakash R, Horsfall M, Markwick A, Pumar M, Lee L, Sinhal A, Joseph MX, Chew DP. Prognostic impact of moderate or severe mitral regurgitation (MR) irrespective of concomitant comorbidities: a retrospective matched cohort study. BMJ Open 2014;4(7), 10.1136/bmjopen-2014-004984.
18. th International Symposium on Intensive Care and Emergency Medicine: Brussels, Belgium, March 18-21, 2014.
19. Bakal JA, Roe MT, Ohman EM, Goodman SG, Fox KA, Zheng Y, Westerhout CM, Hochman JS, Lokhnygina Y, Brown EB, Armstrong PW. Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. European Heart Journal 2015;36(6): 385–392a.
20. Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. Statistics in Medicine 1999;18(11): 1341–1354.
21. Luo X, Tian H, Mohanty S, Tsai WY. An alternative approach to confidence interval estimation for the win ratio statistic. Biometrics 2015;71(1): 139–145.
22. Wei LJ, Johnson WE. Combining dependent tests with incomplete repeated measurements. Biometrika 1985;27: 359–364.
23. Dorfman R. A note on the δ-method for finding variance formulae. The Biometric Bulletin 1938;1: 129–137.
24. De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Saliba F, Jonas S, Sudan D, Fung J, Fischer L, Duvoux C, Chavin KD, Koneru B, Huang MA, Chapman WC, Foltys D, Witte S, Jiang H, Hexham JM, Junge G, H2304 Study Group. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. American Journal of Transplantation 2012;12(11): 3008–3020.
25. Ludikhuize J, Brunsveld-Reinders AH, Dijkgraaf MG, Smorenburg SM, de Rooij SE, Adams R, de Maaijer PF, Fikkers BG, Tangkau P, de Jonge E, Cost and Outcomes of Medical Emergency Teams Study Group. Outcomes associated with the nationwide introduction of rapid response systems in the netherlands. Critical Care Medicine 2015;43(12): 2544–2551.
26. Vennix S, Musters GD, Mulder IM, Swank HA, Consten EC, Belgers EH, van Geloven AA, Gerhards MF, Govaert MJ, van Grevenstein WM, Hoofwijk AG, Kruyt PM, Nienhuijs SW, Boermeester MA, Vermeulen J, van Dieren S, Lange JF, Bemelman WA, Ladies trial colloborators. Laparoscopic peritoneal lavage or sigmoidectomy for perforated diverticulitis with purulent peritonitis: a multicentre, parallel- group, randomised, open-label trial. Lancet 2015;386(10000): 1269–1277.